Why the study?
To assess the effect of flavonoid-rich extract from Gongronema latifolium against cardiomyopathy in streptozotocin-induced diabetic rats.
Does flavonoid-rich extract from Gongronema latifolium improve diabetic cardiomyopathy in streptozotocin-induced diabetic rats?
Does flavonoid-rich extract from Gongronema latifolium improve diabetic cardiomyopathy in streptozotocin-induced diabetic rats?
Flavonoid-rich extract from Gongronema latifolium ameliorates diabetic cardiomyopathy in a rat model by improving metabolic parameters, cardiac enzymes, and modulating serpin A3 and socs3-a gene expression.
Hypothesis-generating in streptozotocin diabetic rats; leaves open any role for Gongronema latifolium extract in human cardiomyopathy.
Introduction The present study access the effect of the flavonoid-rich extract from Gongronema latifolium against cardiomyopathy streptozotocin-induced diabetic rats.Materials and methods The flavonoid-rich extract from G. latifolium leaf (FREGL) was prepared using a standard method. Diabetes was induced by a single intraperitoneal (i.p.) injection of streptozotocin. The experimental animals were divided into five groups as non-diabetic rats, diabetic control, diabetic rats administered low and high doses of FREGL (13 and 26 mg/kg), and metformin-glibenclamide orally for 21 days. Hence, the experimental animals were sacrificed; blood and heart were harvested to determine diverse biochemical parameters, including the gene expressions of serpin A3 and socs3-a as well as histological examination.Results The results demonstrated that FREGL significantly (p < 0.05) reduced fasting blood glucose, total cholesterol, low density lipoprotein (LDL), triglyceride (TG), lipid peroxidation levels, as well as the activities of lactate dehydrogenase and creatine kinase-MB, including the relative gene expressions of serpin A3 and Socs3-A in diabetic rats. Also, diabetic rats that received different doses of FREGL showed a substantial rise in insulin and high density lipoprotein (HDL) levels, antioxidant enzyme activities, as well as, normal histoarchitecture of the heart tissues.Conclusion Therefore, FREGL may be beneficial in alleviating diabetic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Oyinloye et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: